US Brand Name(s) for Idelalisib: Zydelig
Use in Cancer Treatment
Idelalisib is authorized for usage alone or in combination with other medications to treat:
- Recurrence of chronic lymphocytic leukemia (CLL) (come back). It is given in combination with rituximab to patients who cannot be treated with rituximab alone.
- Recurrence of non-Hodgkin lymphoma (NHL) (come back). It is prescribed for individuals who have already had two systemic therapies. It’s utilized in the following NHL types:
- Non-Hodgkin lymphoma of the follicular B-cell type.
- Lymphocytic lymphoma of the small lymphocytes.
The FDA’s Accelerated Approval Program has authorized these uses. A confirmatory study (or trials) must prove that idelalisib offers a therapeutic benefit in these individuals as a condition of approval.
Idelalisib is also a kind of Idelalisib.
This drug’s detailed scientific definition and additional names may be found in the NCI Drug Dictionary. Definition from the NCI Drug Dictionary –
Idelalisib Facts on MedlinePlus – A summary of key information regarding this medication in layman’s terms, which may contain the following:
cautions about this medicine, what it’s used for and how it’s used, what you should tell your doctor before taking it, what you should know about it before using it, other drugs that might interact with it, and possible negative effects
Drugs are frequently investigated to see whether they can assist treat or prevent conditions other than those for which they have been authorized. Only authorized uses of the medication are covered by this patient information leaflet. Much of the material, though, might also apply to authorized uses that are being investigated.